Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329870 | 0.84 | SOS1 (0.58) | SOS1KCNH2KDM4EDPP4HTR2A | |
| SCHEMBL3643057 | 0.83 | SOS1 (0.77) | SOS1KCNH2KDM4EHTR2AHRH1 | |
| SCHEMBL2433881 | 0.79 | SOS1 (0.51) | SOS1KDM4ETAAR1HTR2AHRH1 | |
| SCHEMBL9973125 | 0.79 | KCNH2 (0.47) | SOS1KCNH2HTR2AHRH1ALDH1A1 | |
| SCHEMBL9973123 | 0.79 | KCNH2 (0.47) | SOS1KCNH2HTR2AHRH1ALDH1A1 | |
| SCHEMBL3642467 | 0.79 | KCNH2 (0.53) | SOS1KCNH2DPP4HTR2AHRH1 | |
| SCHEMBL11796932 | 0.78 | KCNH2 (0.76) | KCNH2HTR2AHRH1ALDH1A1EPHX2 | |
| SCHEMBL14310488 | 0.77 | RAB9A (0.56) | EPHX2 | |
| Hydrochloric Acid SCHEMBL11794831 | 0.76 | KCNH2 (0.73) | KCNH2HTR2AHRH1ALDH1A1EPHX2 | |
| SCHEMBL4741840 | 0.76 | RAD52 (0.50) | KDM4ETAAR1CXCR4ALDH1A1CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513825-B1 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Dept of Health and Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-1513825-B1 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Dept of Health and Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2007005896-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| EP-1513825-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Department of Health and Human Services (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | SOS1 4264/4885KCNH2 3808/4885KDM4E 2144/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | SOS1 4390/4885KCNH2 3931/4885KDM4E 2394/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | SOS1 4164/4885KCNH2 4219/4885KDM4E 1205/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | SOS1 4164/4885KCNH2 4219/4885KDM4E 1205/4885 |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | SOS1 4164/4885KCNH2 4219/4885KDM4E 1205/4885 |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | TYMS, TERT, TYMP | SOS1 4718/4885KCNH2 3877/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.